ArticleLung cancer management2012
The role of estrogen, progesterone and aromatase in human non-small-cell lung cancer.
Article in Lung cancer management, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 32 citations in OpenAlex.
- Randomized phase II study of fulvestrant and erlotinib compared with erlotinib alone in patients with advanced or metastatic non-small cell lung cancer.Lung cancer (Amsterdam, Netherlands) · 2018Trial
- Novel Host Pathways Govern Epithelial Cell Invasion of Aspergillus fumigatus.Microbiology spectrum · 2023Article
- Sex Differences in Lung Cancer.Cancers · 2023Review
- Sex-specificity in Surgical Stages of Lung Cancer in Young Adults.The open respiratory medicine journal · 2023Article
- Estrogen induces the expression of EBV lytic protein ZEBRA, a marker of poor prognosis in nasopharyngeal carcinoma.Cancer science · 2022Article
- The Tri-iodothyronine (T3) Level Is a Prognostic Factor for Patients With Advanced NSCLC: Receiving Immune Checkpoint Inhibitors and Is Associated With Liver Metastasis.Clinical Medicine Insights. Oncology · 2022Article
- Role of sex hormones in lung cancer.Experimental biology and medicine (Maywood, N.J.) · 2021Review
- Investigation of Combination Treatment With an Aromatase Inhibitor Exemestane and Carboplatin-Based Therapy for Postmenopausal Women With Advanced NSCLC.JTO clinical and research reports · 2021Article
- In Vitro Transformation of Human Bronchial Epithelial Cells by Diesel Exhaust Particles: Gene Expression Profiling and Early Toxic Responses.Toxicological sciences : an official journal of the Society of Toxicology · 2018Article
- Potential Mechanisms of Age Acceleration Caused by Estrogen Deprivation: Do Endocrine Therapies Carry the Same Risks?JNCI cancer spectrum · 2018Review
- Exploring estrogenic activity in lung cancer.Molecular biology reports · 2017Review
- Sex Differences and Bone Metastases of Breast, Lung, and Prostate Cancers: Do Bone Homing Cancers Favor Feminized Bone Marrow?Frontiers in oncology · 2017Review
- Association between the CYP11 family and six cancer types.Oncology letters · 2016Article
- Intra- and interspecies gene expression models for predicting drug response in canine osteosarcoma.BMC bioinformatics · 2016Article
- Overexpression of estrogen receptor beta is a prognostic marker in non-small cell lung cancer: a meta-analysis.International journal of clinical and experimental medicine · 2015Article
- LRIG2 expression and prognosis in non-small cell lung cancer.Oncology letters · 2014Article
- Survival in women with NSCLC: the role of reproductive history and hormone use.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
Abstract
Lung cancer is the leading cause of cancer-related deaths in both men and women worldwide. Despite advances in treatment, patients have few effective therapeutic options and survival rates remain low. Emerging evidence suggests that the hormones estrogen and progesterone play a key role in the progression of non-small-cell lung cancer (NSCLC). The aromatase enzyme, which is responsible for a key step in estrogen biosynthesis, elicits higher levels of estrogen in lung tumors as well as in metastases compared with nonmalignant tissues. Thus, aromatase may prove to be a key predictive biomarker for treatment of NSCLC. Epidemiologic and preclinical data show estrogens play a critical role in lung tumor development and progression. Two estrogen receptors, α and β, are expressed in normal and in cancerous lung epithelium, and estrogen promotes gene transcription that stimulates cell proliferation and inhibits cell death. Furthermore, expression of both forms of estrogen receptor, progesterone receptor and aromatase in NSCLC specimens has been correlated with worse clinical outcomes. Combination therapies that include estrogen receptor downregulators and aromatase inhibitors are currently being assessed in Phase I-II clinical trials among patients with advanced NSCLC. Results will help guide future lung cancer management decisions, with a goal of achieving more effective and less toxic treatments for patients.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.